Seattle Genetics posted Seattle Genetics Reports First Quarter 2019 Financial Results | Seattle Genetics Inc Seattle Genetics Bothell, WA:

Seattle Genetics Reports First Quarter 2019 Financial Results

-ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada Were $135.0 Million in the First Quarter, an Increase of 42 Percent Over the First Quarter of 2018- -Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Support Planned

QR Code
Embed the QR code on your website:
Download
Copy